Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 19/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 7/20 | 0.43 |
| ▸ | NSD2 | O96028 | 3/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20720716 | 0.93 | EHMT2 (0.50) | EHMT2DNMT1 | |
| SCHEMBL20720768 | 0.92 | AVPR1B (0.43) | EHMT2DNMT1NSD2 | |
| SCHEMBL20720729 | 0.90 | EHMT2 (0.52) | EHMT2DNMT1NSD2 | |
| SCHEMBL20720618 | 0.88 | EHMT2 (0.38) | EHMT2DNMT1NSD2HTR4 | |
| SCHEMBL20720655 | 0.86 | FLT3 (0.42) | — | |
| SCHEMBL20720717 | 0.85 | LCK (0.40) | EHMT2DNMT1HTR4 | |
| Trifluoroacetic Acid SCHEMBL20720681 | 0.85 | EHMT2 (0.55) | EHMT2DNMT1NSD2 | |
| SCHEMBL20720718 | 0.84 | CACNA2D1 (0.46) | EHMT2HTR4 | |
| SCHEMBL20720751 | 0.84 | CACNA2D1 (0.46) | EHMT2HTR4 | |
| SCHEMBL20336970 | 0.83 | EHMT2 (0.44) | EHMT2DNMT1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EHMT2 2/4885DNMT1 32/4885NSD2 127/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885DNMT1 32/4885NSD2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.